The White House Just Changed Psychedelic Policy. Here's What it Means and What is Missing

Something significant happened recently, and I’ve been sitting with it. It goes deeper than psychedelic policy.

President Trump signed an executive order directing the FDA to fast-track review of psychedelic medicines — psilocybin, ibogaine, MDMA, and related compounds — for serious mental illness. Fifty million dollars in federal funding. Priority review vouchers. A formal signal that the decades-long research blockade is over.

My honest reaction is excited, but as per usual, complicated. And I think yours might be too.

The Case for Optimism Is Real

Treatment-resistant depression, PTSD, addiction — the standard toolkit has let millions of people down. The research on psilocybin and ibogaine in particular is genuinely compelling, not in a hype-cycle way but in a “this data keeps holding up” way.

The clinical evidence is striking. A landmark 2021 trial published in NEJM found psilocybin-assisted therapy produced rapid, sustained reductions in depression scores — with an effect size that outpaced conventional antidepressants in comparative trials [1]. A separate randomized controlled trial published in JAMA Psychiatry the same year reported that two doses of psilocybin produced large, significant antidepressant effects that persisted at four-week follow-up in patients with major depressive disorder [2]. Ibogaine has shown remarkable promise for opioid use disorder and treatment-resistant PTSD in veteran populations, with a recent Stanford study documenting dramatic reductions in disability and suicidality [3].

Accelerating regulatory review means more people may access something that can actually help them. That matters enormously.

But Here’s the Pattern I Keep Noticing

We’ve watched this happen before — not with psychedelics, but with food, with supplements, with gut health, with metabolic medicine. A powerful natural intervention, steeped in centuries of cultural context, gets “discovered” by modern science, then quietly absorbed into a pharmaceutical and corporate framework. The plant gets patented. The protocol gets standardized. The nuance gets stripped out. And the people who most need it — who lack access to the integrative, supportive context that makes the intervention work — often get the least benefit while bearing the most risk.

I’m not saying that’s inevitable here. But it’s the track record, and it’s worth naming.

What the Clinical Research Doesn’t Fully Capture: The Biology of Preparation and Integration

This is where my work intersects with the psychedelic conversation in ways that don’t get discussed enough.

The outcomes from psychedelic-assisted therapy are not uniform, and the variation isn’t random. Your nutritional status, your inflammatory burden, your gut-brain axis, your methylation capacity, your cortisol patterns — these aren’t background noise. They are active variables in how your nervous system responds to and integrates a profound neurochemical experience.

Serotonin synthesis depends on tryptophan availability and B-vitamin cofactors (particularly B6, folate, and B12). Dietary tryptophan is the sole precursor to serotonin, and deficiencies in these cofactors measurably impair neurotransmitter production [4]. Since psilocybin and other serotonergic psychedelics act primarily on 5-HT2A receptors, the baseline state of a person’s serotonergic system — shaped in part by nutritional status — is relevant to therapeutic response.

Neuroplasticity — the proposed mechanism by which these medicines create durable change — is exquisitely sensitive to metabolic conditions. Groundbreaking research from Gül Dölen’s lab at Johns Hopkins has demonstrated that psychedelics reopen critical learning periods in the brain (what neuroscientists call “metaplasticity”), windows of heightened sensitivity that were previously thought to close permanently after childhood [5]. Ketamine exerts its rapid antidepressant effects, in part, through the mTOR pathway, thereby driving synaptic spine formation and reversing neuronal atrophy caused by chronic stress [6]. But here’s what the clinical trials don’t ask: what is the inflammatory milieu in which that neuroplasticity is occurring?

Chronic neuroinflammation is now understood to be a core feature of treatment-resistant depression, not merely a correlate of it [7]. A brain operating under elevated inflammatory load — driven by poor diet quality, gut dysbiosis, metabolic dysfunction, or unresolved trauma — processes altered states differently than a well-nourished, biochemically supported one. The gut-brain axis, via vagal afferents and circulating immune signals, directly modulates the central serotonergic and glutamatergic systems that psychedelics engage [8].

None of this is in the FDA’s fast-track criteria. None of it will appear on a standardized dose protocol.

The Harder Question Underneath All of This: What Do We Actually Mean by Healing?

Pharmaceutical frameworks are designed to answer a specific, narrow version of that question. They’re built to demonstrate symptom reduction in controlled populations over defined time periods. That’s not nothing — it’s how we generate scalable evidence. But it doesn’t answer questions like: Is this person prepared? Are they supported? What happens in the months after? What’s their relationship to their own body, to meaning, to community?

The field has a term for it: integration. Researchers Settee and Shukla define it as an active process through which a person revisits, makes sense of, and gradually incorporates the insights of a psychedelic experience into their daily life — internally (mind, body, spirit) and externally (relationships, lifestyle, the natural world) [9]. Integration isn’t an add-on. It’s the mechanism through which the neuroplastic window opened by the medicine gets used. Miss it, and the elevated state fades into memory.

These questions have always been at the center of serious psychedelic practice. They’re also, not coincidentally, at the center of everything I think about in the nutrition and mental health space — how to create the biological and relational conditions under which insight actually sticks.

What I Believe

The executive order is a door opening. What walks through that door depends on whether the field can hold onto its most important insights even as the corporate machinery revs up. That means keeping the conversation grounded in biology — real, individual, testable biology — not just symptom checklists and standardized doses.

It means asking, before the medicine is even administered: How is this person’s gut-brain axis? What’s their inflammatory status? Are they nutritionally depleted? Are they prepared — psychologically, somatically, relationally? And after: What support exists to help them translate the experience into lasting change?

These aren’t fringe questions. They’re the questions that functional medicine has been asking for years. And they’re increasingly supported by the mechanistic science underlying why psychedelics work at all.

There’s a lot more to say here about psychedelic medicine and policy. I’ll keep saying it.

References

1. Carhart-Harris R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–1411.
2. Davis AK, et al. Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry. 2021;78(5):481–489.
3. Cherian KN, et al. Magnesium-ibogaine therapy in veterans with traumatic brain injury. Nat Med. 2024;30:373–381.
4. Young SN. How to increase serotonin in the human brain without drugs. J Psychiatry Neurosci. 2007;32(6):394–399.
5. Nardou R, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023;618:790–798.
6. Li N, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964.
7. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34.
8. Mayer EA, et al. Gut/brain axis and the microbiota. J Clin Invest. 2015;125(3):926–938.
9. Settee A, Shukla M. Integration in psychedelic-assisted therapy. 2020.